1'-methylascorbigen is a synthetic analog of ascorbigen, a natural compound found in plants. Ascorbigen is formed from ascorbic acid (vitamin C) through a series of enzymatic reactions.
**Here's why 1'-methylascorbigen is important for research:**
* **Antioxidant Properties:** 1'-methylascorbigen exhibits potent antioxidant activity, scavenging free radicals and protecting cells from oxidative damage. This makes it a promising candidate for studying and treating various diseases associated with oxidative stress, such as cancer, neurodegenerative disorders, and cardiovascular diseases.
* **Anti-inflammatory Properties:** Studies have shown that 1'-methylascorbigen possesses anti-inflammatory properties, inhibiting the production of inflammatory mediators like cytokines and chemokines. This makes it a potential therapeutic agent for inflammatory conditions like arthritis and inflammatory bowel disease.
* **Improved Bioavailability:** Compared to ascorbigen, 1'-methylascorbigen has enhanced bioavailability, meaning it can be absorbed and utilized more efficiently by the body. This makes it a more desirable molecule for drug development and therapeutic applications.
* **Potential for Cancer Therapy:** Preclinical studies have shown that 1'-methylascorbigen can inhibit the growth and proliferation of cancer cells, potentially due to its antioxidant and anti-inflammatory properties. This suggests that 1'-methylascorbigen could be a valuable tool in cancer treatment research.
* **Neuroprotective Effects:** Research indicates that 1'-methylascorbigen may offer neuroprotective effects by reducing oxidative stress and inflammation in the brain. This makes it a potential candidate for treating neurodegenerative diseases like Alzheimer's and Parkinson's disease.
**Ongoing Research:**
Researchers are currently exploring the therapeutic potential of 1'-methylascorbigen in various disease models. Studies are ongoing to evaluate its efficacy, safety, and mechanisms of action in different contexts.
**Important Note:**
1'-methylascorbigen is still under investigation, and its safety and efficacy in humans haven't been fully established. More research is needed before it can be considered a safe and effective treatment option.
1'-methylascorbigen: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 130308 |
| MeSH ID | M0201815 |
| Synonym |
|---|
| 92557-61-4 |
| 1'-methylascorbigen |
| ccris 6834 |
| beta-l-threo-l-glycero-3-hexulofuranosonic acid, 2-c-((1-methyl-1h-indol-3-yl)methyl)-, gamma-lactone |
| A845848 |
| (3s,3ar,6s,6as)-3,6,6a-trihydroxy-6-[(1-methyl-3-indolyl)methyl]-3,3a-dihydro-2h-furo[3,2-b]furan-5-one |
| (3s,3ar,6s,6as)-6-[(1-methylindol-3-yl)methyl]-3,6,6a-tris(oxidanyl)-3,3a-dihydro-2h-furo[3,2-b]furan-5-one |
| DTXSID901034330 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effectiveness of protection depends - as in the case of other endogenous, N-methylated compounds - on the dosage of applied 1'-methylascorbigen and on the time interval between the chemical pretreatment and inoculation." | ( Effect of 1-methylascorbigen on the resistance potential of plants to pathogens. Kátay, G; Tyihák, E, 1998) | 0.51 |
| " The effectiveness of protection depended on the dosage of the applied l'-methylascorbigen and on the time interval between the chemical pretreatment and inoculation." | ( Effect of ascorbigen and 1'-methylascorbigen on disease resistance of bean plants to Uromyces phaseoli. Kátay, E; Kátay, G; Tyihák, E, 2011) | 0.67 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||